Prosecution Insights
Last updated: November 12, 2026
Application No. 18/832,996

GEMCITABINE LIPOSOME PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF

Final Rejection §103
Filed
Jul 25, 2024
Priority
Mar 25, 2022 — CN 202210300041.7 +1 more
Examiner
SONG, JIANFENG
Art Unit
1613
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hunan Kelun Pharmaceutical Research Co. Ltd.
OA Round
2 (Final)
56%
Grant Probability
Moderate
3-4
OA Rounds
89%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
492 granted / 872 resolved
-3.6% vs TC avg
Strong +33% interview lift
Without
With
+32.8%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
68 currently pending
Career history
950
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Withdrawn Rejections: Applicant's amendments and arguments filed on 09/14/2026 are acknowledged and have been fully considered. The Examiner has re-weighed all the evidence of record. Any rejection and/or objection not specifically addressed below is herein withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set of rejections and/or objections presently being applied to the instant application. Claims 1-9 and 11-20 are pending, claims 1-3 and 12 are under examination. Information Disclosure Statement The information disclosure statement (IDS) submitted on 06/22/2026 is being considered by the examiner. Priority Acknowledge is made that this application is national stage of international patent application PCT/CN2023/081594, filed on 03/15/2023; which claims priority from Chinese Patent Application CN202210300041.7, filed on 03/25/2022. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 1-3 and 12 are rejected under 35 U.S.C. 103 as being unpatentable over Wu et al. (CN11103561A, Google Translation). Determination of the scope and content of the prior art (MPEP 2141.01) Wu et al. teaches Gemcitabine liposome comprising gemcitabine, phospholipids, cholesterol, phosphatidylethanolamine, sulfate and a buffer (claim 1). The gemcitabine liposome comprises, by weight, 1 to 10 parts of gemcitabine, 1 to 10 parts of phospholipids, 0.1 to 5 parts of cholesterol, 0.1 to 5 parts of phosphatidylethanolamine, 0.1 to 2 parts of sulfate, and 1 to 5 parts of buffer (claim 2). phospholipid comprises any one or a combination of at least two of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylcholine, or lecithin; preferably a combination of hydrogenated soy phosphatidylcholine, distearoyl phosphatidylcholine and lecithin; preferably, the sulphate comprises ammonium sulphate and/or a sucrose octasulphate salt, preferably a combination of ammonium sulphate and a sucrose octasulphate salt (claim 4). The buffer comprises sucrose and/or glucose, preferably a combination of sucrose and glucose (claim 5). The aqueous phase includes gemcitabine, sulfate, buffet and water to have concentration of gemcitabine is 1-10mg/mL, and the particle size of the liposome is 30-150 nm (claim 9). Ascertainment of the difference between the prior art and the claims (MPEP 2141.02) The difference between the instant application and Wu et al. is that Wu et al. do not expressly teach all limitation in one embodiment. Finding of prima facie obviousness Rational and Motivation (MPEP 2142-2143) It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to produce the instant invention. Wu et al. teaches Gemcitabine liposome comprising phospholipids, cholesterol and phosphatidylethanolamine as oil phase, gemcitabine, sulfate and a buffer as aqueous phase. By definition of liposome, oil phase comprising phospholipids, cholesterol and phosphatidylethanolamine forming a lipophilic layer encapsulating an aqueous core comprising gemcitabine, sulfate and a buffer. Wu et al. further teaches the gemcitabine liposome comprises, by weight, 1 to 10 parts of gemcitabine, 1 to 10 parts of phospholipids (hydrogenated soy phosphatidylcholine), 0.1 to 5 parts of cholesterol, 0.1 to 5 parts of phosphatidylethanolamine, 0.1 to 2 parts of sulfate, and 1 to 5 parts of buffer; and concentration of gemcitabine is 1-10mg/mL. Regarding the weight ratio of phospholipid to cholesterol, Wu et al. further teaches 7-8 parts of phospholipid to 1 parts cholesterol, the ratio is 7:1 to 8:1. Regarding long-circulating functional material, since it is optional, it can always be omitted. Regarding the total lipid to gemcitabine, Wu et al. further teaches 7-8 parts of phospholipid to 1 parts cholesterol to 1 parts of phosphatidylethanolamine and 1 parts of gemcitabine, the weight ratio is (7+1+1):1= 9:1, inside of claimed range of 1:1 to 100:1. Regarding molar concentration of salt (ammonium sulfate), for 1 part of gemcitabine at 10mg/mL, and 2 parts of ammonium sulfate ( MW132) would be 20mg/ml (20000mg/l), and 20000mg/l divided by 132 gives 152mM, inside claimed range of 50 to 800mM. Regarding claim 2-3 and 12, the particle size is 30-150 nm, inside of claimed range of 10 to 200nm or encompassing claimed range of 50 to 100nm. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103. From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art before the effective filing date of the claimed invention, as evidenced by the references, especially in the absence of evidence to the contrary. Response to Argument: Applicants argue that there is no teaching of amended claim. In response to this argument: this is not persuasive. The new ground 103 rejection teaches each limitation of applicant’s claimed invention. MPEP 2141 III states: “The proper analysis is whether the claimed invention would have been obvious to one of ordinary skill in the art after consideration of all the facts.” Respectfully, after weighing all the evidence, the Examiner has reached a determination that the instant claims are not patentable in view of the preponderance of evidence and consideration of all the facts which is more convincing than the evidence which has been offered in opposition to it. Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JIANFENG SONG. Ph.D. whose telephone number is (571)270-1978. The examiner can normally be reached M-F 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Brian-Yong Kwon can be reached at (571)272-0581. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JIANFENG SONG/Primary Examiner, Art Unit 1613
Read full office action

Prosecution Timeline

Jul 25, 2024
Application Filed
Jun 16, 2026
Non-Final Rejection mailed — §103
Sep 14, 2026
Response Filed
Oct 28, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773378
METHOD FOR THE COSMETIC TREATMENT OF KERATIN FIBRES COMPRISING A STAGE OF APPLICATION OF A RARE EARTH METAL COMPOSITION AND A STAGE OF APPLICATION OF A COMPOSITION COMPRISING SURFACTANTS
4y 4m to grant Granted Oct 27, 2026
Patent 12773382
BIOFILM REMOVER AND BIOFILM REMOVAL METHOD
2y 10m to grant Granted Oct 27, 2026
Patent 12766106
MICROPARTICLES CONTAINING MOXIDECTIN, AND PREPARATION METHOD THEREFOR
2y 8m to grant Granted Oct 20, 2026
Patent 12758519
FELINE FOOD COMPOSITION
5y 2m to grant Granted Oct 13, 2026
Patent 12734134
HERBAL BIOACTIVES BASED IMMUNOSTIMULANT FORMULATION FOR POULTRY BIRDS & CATTLE AND PREPARATION THEREOF
3y 1m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
56%
Grant Probability
89%
With Interview (+32.8%)
Moderate
PTA Risk
Based on 872 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month